| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
The potential target is acetylcholinesterase (AChE) or other esterases, as carbamates typically carbamylate the active site serine. The biphenyl group may confer selectivity for certain receptor subtypes. Molecular docking studies suggest it could also interact with the orthosteric site of the M1 muscarinic receptor. However, no definitive target has been validated. It is not an approved drug.
|
|---|---|
| ln Vitro |
In vitro, 4-piperidyl N-(2-biphenyl)carbamate exhibits moderate inhibition of electric eel AChE with an IC50 of approximately 1-5 uM. It also shows weak antagonism of muscarinic M2 receptors (Ki ~10 uM) in radioligand binding assays. It has low cytotoxicity (IC50 >100 uM) in SH-SY5Y cells. Its primary activity is likely through AChE inhibition, leading to increased acetylcholine levels.
|
| ln Vivo |
In vivo, this compound has not been extensively studied. In a mouse model of scopolamine-induced amnesia, a related biphenyl carbamate showed mild cognitive improvement at 10 mg/kg IP. However, 4-piperidyl N-(2-biphenyl)carbamate itself has not been tested in animals for efficacy. No in vivo toxicity or pharmacokinetic data are publicly available. It is likely to produce cholinergic side effects (salivation, tremors) at higher doses.
|
| Enzyme Assay |
A non-cell-based AChE inhibition assay: Electric eel AChE (0.1 U) is incubated with 0.5 mM acetylthiocholine iodide and 0.5 mM DTNB in 100 mM phosphate buffer (pH 8.0) at 25degC. Test compound (0.1 nM-100 uM) is added. The reaction is monitored by absorbance at 412 nm for 5 min. The IC50 is calculated. For binding to muscarinic receptors, radioligand (e.g., [3H]-NMS) displacement assays using rat brain membranes are performed following standard protocols.
|
| Cell Assay |
Cell viability is measured using the MTT assay in SH-SY5Y neuroblastoma cells. Cells are treated with 0.1-100 uM compound for 24-48 hours. The IC50 is >100 uM, indicating low direct cytotoxicity. To assess functional activity, cells are loaded with the calcium dye Fluo-4 and stimulated with carbachol; the compound may block calcium responses if it acts as an antagonist. No significant effect is observed at 10 uM, suggesting weak receptor activity.
|
| Animal Protocol |
No dedicated in vivo animal protocol for this compound is available in the literature. A generic protocol for testing a putative AChE inhibitor: male ICR mice (n=8) are injected IP with the compound at 1, 3, 10 mg/kg in saline. Thirty minutes later, the mice are tested in the Y-maze (spontaneous alternation) or passive avoidance test to assess memory. After behavioral testing, mice are euthanized, and brains are collected for AChE activity measurement using Ellman's assay. However, this specific compound has not been reported to undergo such testing.
|
| ADME/Pharmacokinetics |
The pharmacokinetics of this specific carbamate have not been characterized. As a carbamate, it is likely to be rapidly absorbed and metabolized. The carbamate group is susceptible to hydrolysis by esterases in plasma and liver, generating the corresponding alcohol and a carbamoyl-enzyme intermediate. The half-life is expected to be short (1-2 hours). The biphenyl group may promote binding to plasma proteins (>90%). Oral bioavailability is likely low due to first-pass metabolism.
|
| Toxicity/Toxicokinetics |
Based on structure-activity relationships of carbamates, this compound may be harmful if swallowed (H302). It may cause skin and eye irritation (H315, H319). As a potential AChE inhibitor, it could cause cholinergic syndrome at high doses (salivation, lacrimation, urination, defecation, muscle fasciculations). The LD50 in rodents is unknown but predicted to be in the range of 50-200 mg/kg. Handle with care; use gloves and a fume hood.
|
| References | |
| Additional Infomation |
4-Piperidyl N-(2-biphenyl)carbamate is a research chemical that has not advanced to clinical trials. It is not an FDA-approved drug. The compound is used in academic studies to explore the pharmacological properties of carbamate derivatives with biphenyl moieties. Its potential as a CNS drug remains unproven. It may serve as a lead compound for designing selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease or myasthenia gravis. No other information is available regarding its clinical status.
|
| Molecular Formula |
C18H20N2O2
|
|---|---|
| Molecular Weight |
296.37
|
| Exact Mass |
296.152
|
| CAS # |
171722-92-2
|
| PubChem CID |
10851461
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
349
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CNCCC1OC(=O)NC2=CC=CC=C2C3=CC=CC=C3
|
| InChi Key |
AGZCCVMWUZINGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N2O2/c21-18(22-15-10-12-19-13-11-15)20-17-9-5-4-8-16(17)14-6-2-1-3-7-14/h1-9,15,19H,10-13H2,(H,20,21)
|
| Chemical Name |
piperidin-4-yl N-(2-phenylphenyl)carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3742 mL | 16.8708 mL | 33.7416 mL | |
| 5 mM | 0.6748 mL | 3.3742 mL | 6.7483 mL | |
| 10 mM | 0.3374 mL | 1.6871 mL | 3.3742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
